Patent 7271149 was granted and assigned to Eli Lilly on September, 2007 by the United States Patent and Trademark Office.
The present invention relates to glucagon-like-1 compounds fused to proteins that have the effect of extending the in vivo half-life of the peptides. These fusion proteins can be used to treat non-insulin dependent diabetes mellitus as well as a variety of other conditions.